The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. the results of a phase I/II study

European Journal of Cancer

Volumn 50, Issue 8, 2014, Pages 1422-1429

  Watkins, D J ^a   Starling, N ^a   Cunningham, D ^a   Thomas, J ^a   Webb, J ^a   Brown, G ^a   Barbachano, Y ^a   Oates, J ^a   Chau, I ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Anti angiogenic therapy; Chemotherapy; Combination chemotherapy; Epidermal growth factor receptor (EGFR) inhibition; Molecularly targeted therapy; Pancreatic cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; ERLOTINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; INTESTINE OBSTRUCTION; LETHARGY; MALE; MULTIPLE CYCLE TREATMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECOMMENDED DRUG DOSE; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; STOMATITIS; SURVIVAL RATE; VENOUS THROMBOEMBOLISM; WOUND HEALING;

ANTI-ANGIOGENIC THERAPY; CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITION; MOLECULARLY TARGETED THERAPY; PANCREATIC CANCER;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; QUINAZOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84898867186     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.02.003     Document Type: Article

References (28)

1. CRUK. 2012. Available from infocancerresearchuk.org/cancerstats/types/ pancreas/mortality/#Trends. [accessed 21.1.14].
2. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 4 2010 765 781
3. H.A. Burris III, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, and M.R. Modiano et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 1997 2403 2413 (Pubitemid 27251144)
4. D. Cunningham, I. Chau, D.D. Stocken, J.W. Valle, D. Smith, and W. Steward et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 33 2009 5513 5518
5. V. Heinemann, R. Labianca, A. Hinke, and C. Louvet Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study Ann Oncol 18 10 2007 1652 1659 (Pubitemid 47514482)
6. M.J. Moore, D. Goldstein, J. Hamm, A. Figer, J.R. Hecht, and S. Gallinger et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 15 2007 1960 1966 (Pubitemid 46972777)
7. T. Conroy, F. Desseigne, M. Ychou, O. Bouche, R. Guimbaud, and Y. Becouarn et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 19 2011 1817 1825
8. D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, and M. Moore et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 18 2013 1691 1703
9. Amgen. 2012. Available from http://www.amgen.com/media/media-pr-detail. jsp?releaseID=1723925. [accessed 20.1.14].
10. H.L. Kindler, T. Ioka, D.J. Richel, J. Bennouna, R. Letourneau, and T. Okusaka et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study Lancet Oncol 12 3 2011 256 262
11. P.A. Philip, J. Benedetti, C.L. Corless, R. Wong, E.M. O'Reilly, and P.J. Flynn et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205 J Clin Oncol 28 22 2010 3605 3610
12. L.M. Ellis Epidermal growth factor receptor in tumor angiogenesis Hematol Oncol Clin North Am 18 5 2004 1007 1021 viii (Pubitemid 39335756)
13. G.N. Naumov, M.B. Nilsson, T. Cascone, A. Briggs, O. Straume, and L.A. Akslen et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance Clin Cancer Res 15 10 2009 3484 3494
14. A. Viloria-Petit, T. Crombet, S. Jothy, D. Hicklin, P. Bohlen, and J.M. Schlaeppi et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Res 61 13 2001 5090 5101 (Pubitemid 32681540)
15. N. Starling, D. Watkins, D. Cunningham, J. Thomas, J. Webb, and G. Brown et al. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer J Clin Oncol 27 33 2009 5499 5505
16. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
17. M. Reni, S. Cereda, G. Balzano, P. Passoni, A. Rognone, and C. Fugazza et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma Cancer 115 12 2009 2630 2639
18. C. Verslype, E. Van Cutsem, M. Dicato, N. Arber, J.D. Berlin, and M.W. Büchler et al. The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012 Ann Oncol 24 Suppl. 4 2013 iv5 iv10
19. E. Van Cutsem, W.L. Vervenne, J. Bennouna, Y. Humblet, S. Gill, and J.L. Van Laethem et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer J Clin Oncol 27 13 2009 2231 2237
20. M. Scartozzi, R. Giampieri, E. Maccaroni, M. Del Prete, L. Faloppi, and M. Bianconi et al. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients Br J Cancer 106 5 2012 799 804
21. A.F. Sobrero, and P. Bruzzi Vatalanib in advanced colorectal cancer: two studies with identical results J Clin Oncol 29 15 2011 1938 1940
22. G.C. Jayson, S. de Haas, P. Delmar, D.W. Miles, M.A. Shah, and E. Van Cutsem et al. 804 ORAL evaluation of plasma VEGFA as a potential predictive pan-tumour biomarker for bevacizumab Eur J Cancer 47 2011 S96
23. D. Lambrechts, B. Claes, P. Delmar, J. Reumers, M. Mazzone, and B.T. Yesilyurt et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials Lancet Oncol 13 7 2012 724 733
24. Clinicaltrials.gov. Available from http://clinicaltrials.gov/ct2/show/ study/NCT00844649?term=abraxane+pancreatic&rank=16#locn [accessed 20.7.13].
25. J. Tabernero et al. Phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer: Influence of prognostic factors on survival Ann Oncol 24 Suppl. 4 2013 [abstract O-0001]
26. J.L. Ryan, J.K. Carroll, E.P. Ryan, K.M. Mustian, K. Fiscella, and G.R. Morrow Mechanisms of cancer-related fatigue Oncologist 12 Suppl. 1 2007 22 34
27. K.C.H. Fearon Cancer cachexia: developing multimodal therapy for a multidimensional problem Eur J Cancer 44 8 2008 1124 1132
28. D. Lambrechts, H.-J. Lenz, S. de Haas, P. Carmeliet, and S.J. Scherer Markers of response for the antiangiogenic agent bevacizumab J Clin Oncol 31 9 2013 1219 1230